Management to hold conference call at 9:00 a.m. EST
JERUSALEM--(BUSINESS WIRE)--Nov. 5, 2012--
BioLineRx Ltd. (NASDAQ: BLRX)
(TASE: BLRX),
a biopharmaceutical development company, announced today that it will
release its unaudited financial results for the quarter ended September
30, 2012 on Wednesday, November 14, 2012, before the U.S. markets open.
The Company will host a conference call on Wednesday, November 14 at
9:00 a.m. EST featuring remarks by Kinneret Savitsky, Ph.D., CEO of
BioLineRx, and Philip Serlin, Chief Financial and Operating Officer of
BioLineRx. The conference call will be available via webcast and can be
accessed through the Investor Relations section of BioLineRx’s website, www.biolinerx.com,
and www.kcsa.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-407-2553 from the U.S. or
+972-3-918-0610 internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com
or www.kcsa.com.
A dial-in replay of the call will be available until November 17, 2012;
please dial 1-877-456-0009 from the U.S. or +972-3-9255925
internationally.
About BioLineRx
BioLineRx is a publicly-traded
biopharmaceutical development company. BioLineRx is dedicated to
building a portfolio of products for unmet medical needs or with
advantages over currently available therapies. BioLineRx’s current
portfolio consists of six clinical stage candidates: BL-1020 for
schizophrenia is currently undergoing a Phase II/III study; BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for
non-surgical removal of skin lesions has completed a Phase I/II study;
BL-1021 for neuropathic pain is in Phase I development, BL-7040 for
treating inflammatory bowel disease (IBD) currently undergoing a Phase
II trial, and BL-8040 for treating acute myeloid leukemia (AML) and
other hematological cancers has completed Phase I. In addition,
BioLineRx has nine products in various pre-clinical development stages
for a variety of indications, including central nervous system diseases,
infectious diseases, cardiovascular and autoimmune diseases.
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s Office of the Chief Scientist (OCS). The final stage
includes partnering with medium and large pharmaceutical companies for
advanced clinical development (Phase III) and commercialization. For
more information on BioLineRx, please visit www.biolinerx.com.
Source: BioLineRx Ltd.
KCSA Strategic Communications
Garth Russell, 1-212-896-1250
grussell@kcsa.com
or
Todd
Fromer, 1-212-896-1215
tfromer@kcsa.comor
or
Tsipi
Haitovsky, Public Relations
+972-52-598-9892
tsipih@netvision.net.il